AR066820A1 - Compuestos de tiadiazolidin-3 ona - Google Patents
Compuestos de tiadiazolidin-3 onaInfo
- Publication number
- AR066820A1 AR066820A1 ARP080102325A ARP080102325A AR066820A1 AR 066820 A1 AR066820 A1 AR 066820A1 AR P080102325 A ARP080102325 A AR P080102325A AR P080102325 A ARP080102325 A AR P080102325A AR 066820 A1 AR066820 A1 AR 066820A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- thiadiazolidin
- naphthalen
- dioxo
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos que son inhibidores de las fosfatasas de proteína tirosina (PTPasas), y por lo tanto, que se pueden emplear para el tratamiento de las condiciones mediadas por la actividad de PTPasa. Los compuestos de la presente también se pueden emplear como inhibidores de otras enzimas caracterizadas por una region de enlace de fosfotirosina, tal como el dominio SH2. De acuerdo con lo anterior, los compuestos de la presente se pueden emplear para la prevencion y/o el tratamiento de resistencia a la insulina asociada con obesidad, intolerancia a la glucosa, diabetes mellitus, hipertension, y enfermedades isquémicas de los vasos sanguíneos grandes y pequenos, condiciones que acompanan a la diabetes tipo 2, incluyendo hiperlipidemia, hipertrigliceridemia, ateroesclerosis, restenosis vascular, síndrome de intestino irritable, pancreatitis, tumores de células adiposas, y carcinomas, tales como liposarcoma, dislipidemia, y otros trastornos en donde se indique la resistencia a la insulina. En adicion, los compuestos de la presente se pueden emplear para tratar y/o prevenir cáncer, osteoporosis, enfermedades neurodegenerativas e infecciosas, y enfermedades que involucren inflamacion y el sistema inmune. Composicion farmacéutica en base al compuesto y uso del compuesto para preparar medicamentos. Reivindicacion 1: Un compuesto, el cual se selecciona a partir del grupo que consiste en: 5-(3-hidroxi-7-metoxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; 5-(3-hidroxi-7-propoxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; 5-(3-hidroxi-naftalen-2-il)-1,1-dioxo-[1,2,5]-tiadiazolidin-3-ona; y 5-(3-hidroxi-7-metil-naftalen-2-il)-1,1-dioxo-1,2,5-tiadiazolidin-3-ona; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94176807P | 2007-06-04 | 2007-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066820A1 true AR066820A1 (es) | 2009-09-16 |
Family
ID=39720401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102325A AR066820A1 (es) | 2007-06-04 | 2008-06-02 | Compuestos de tiadiazolidin-3 ona |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100197744A1 (es) |
EP (1) | EP2155704A1 (es) |
JP (1) | JP2010529075A (es) |
CN (1) | CN101687828A (es) |
AR (1) | AR066820A1 (es) |
CL (1) | CL2008001612A1 (es) |
PE (1) | PE20090762A1 (es) |
TW (1) | TW200911769A (es) |
WO (1) | WO2008148744A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101321743A (zh) * | 2005-12-08 | 2008-12-10 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途 |
JP2009518420A (ja) * | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | タンパク質チロシンホスファターゼ(ptpase)により介在する状態の処置のために有用である1,2,5−チアゾリジン誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN105232543A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193797A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105520943A (zh) * | 2015-11-11 | 2016-04-27 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232544A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105434433A (zh) * | 2015-11-11 | 2016-03-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287531A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193800A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213381A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232552A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287534A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105250277A (zh) * | 2015-11-11 | 2016-01-20 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213385A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193821A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213380A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213382A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287533A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213383A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232547A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193796A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232546A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105434434A (zh) * | 2015-11-11 | 2016-03-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105250276A (zh) * | 2015-11-11 | 2016-01-20 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213387A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105232545A (zh) * | 2015-11-11 | 2016-01-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105193801A (zh) * | 2015-11-11 | 2015-12-30 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213386A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213379A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105213384A (zh) * | 2015-11-11 | 2016-01-06 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287532A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105412095A (zh) * | 2015-11-11 | 2016-03-23 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105287535A (zh) * | 2015-11-11 | 2016-02-03 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN105476990A (zh) * | 2015-11-11 | 2016-04-13 | 朱忠良 | 一种抗糖尿病的口服药物组合物 |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
TW202100515A (zh) * | 2019-03-14 | 2021-01-01 | 美商嘉來克生命科學有限責任公司 | 蛋白酪胺酸磷酸酶抑制劑及其使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2341049A1 (en) * | 2002-04-03 | 2011-07-06 | Novartis AG | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors |
GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
-
2008
- 2008-06-02 AR ARP080102325A patent/AR066820A1/es unknown
- 2008-06-03 EP EP08760391A patent/EP2155704A1/en not_active Withdrawn
- 2008-06-03 CL CL2008001612A patent/CL2008001612A1/es unknown
- 2008-06-03 WO PCT/EP2008/056807 patent/WO2008148744A1/en active Application Filing
- 2008-06-03 PE PE2008000936A patent/PE20090762A1/es not_active Application Discontinuation
- 2008-06-03 TW TW097120602A patent/TW200911769A/zh unknown
- 2008-06-03 CN CN200880018827A patent/CN101687828A/zh active Pending
- 2008-06-03 US US12/602,709 patent/US20100197744A1/en not_active Abandoned
- 2008-06-03 JP JP2010510761A patent/JP2010529075A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2155704A1 (en) | 2010-02-24 |
JP2010529075A (ja) | 2010-08-26 |
WO2008148744A1 (en) | 2008-12-11 |
CL2008001612A1 (es) | 2009-05-15 |
CN101687828A (zh) | 2010-03-31 |
US20100197744A1 (en) | 2010-08-05 |
TW200911769A (en) | 2009-03-16 |
PE20090762A1 (es) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066820A1 (es) | Compuestos de tiadiazolidin-3 ona | |
ECSP088509A (es) | Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa | |
ECSP088506A (es) | Derivados de tiadiazol como agentes antidiabeticos | |
Pasha et al. | Sestrin2 as a novel biomarker and therapeutic target for various diseases | |
Rehman et al. | Taxifolin prevents postprandial hyperglycemia by regulating the activity of α‐amylase: Evidence from an in vivo and in silico studies | |
Polychronopoulos et al. | Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases | |
Demuro et al. | GSK-3β, FYN, and DYRK1A: master regulators in neurodegenerative pathways | |
Valerio et al. | Glycogen synthase kinase‐3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production | |
BR112021020335A2 (pt) | Agonistas glp-1r e usos dos mesmos | |
Islam et al. | Catalytic asymmetric synthesis of indole derivatives as novel α-glucosidase inhibitors in vitro | |
Oriquat et al. | Improving hepatic mitochondrial biogenesis as a postulated mechanism for the antidiabetic effect of Spirulina platensis in comparison with metformin | |
BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
TNSN08247A1 (en) | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors | |
EA201100119A1 (ru) | Химические соединения 251 | |
WO2007115058A3 (en) | Thiadiazolidinone inhibitors of ptpase | |
EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
Huang et al. | Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation | |
Shorning et al. | Intestinal renin–angiotensin system is stimulated after deletion of Lkb1 | |
CL2007001869A1 (es) | Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e | |
EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
Wang et al. | Comparison of hepatotoxicity and mechanisms induced by triclosan (TCS) and methyl-triclosan (MTCS) in human liver hepatocellular HepG2 cells | |
NO20044745L (no) | 5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer | |
EA200971106A1 (ru) | Соединения с семичленным кольцом и их фармацевтические применения для предупреждения и лечения диабета и метаболического синдрома | |
CL2011001839A1 (es) | Compuestos derivados de tiadiazoles y oxadiazoles, inhibidores de la biosintesis de trigliceridos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de obesidad, dislipidemia, afecciones de alteracion de la glucosa en ayunas, diabetes de tipo 2, entre otras. | |
Gao et al. | Pinostrobin inhibits proprotein convertase subtilisin/kexin-type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |